[Pulmonary metastases from endometrial stromal sarcoma may benefit from hormone therapy].

Abstract

INTRODUCTION:

Low grade endometrial stromal sarcoma (ESS) often expresses oestrogen (ER) and progesterone (PR) receptors, even in metastatic disease. These receptors may also be hormone dependent.

CASE REPORT:

Two years after the institution of oestrogen replacement therapy (HRT) a woman of 56 presented with haemoptysis which led to the discovery of multiple pulmonary nodules. Twelve years previously the patient had had a hysterectomy for a low grade endometrial stromal sarcoma, ER and PR positive. Surgical resection of the nodules on the right side confirmed the diagnosis of metastatic endometrial stromal sarcoma. The metastases expressed oestrogen and progesterone receptors. Three months after the withdrawal of HRT and treatment with an aromatase inhibitor (letrozole) the contralateral metastases had disappeared and this complete response was maintained for more than 2 years of follow-up.

CONCLUSION:

Care should be taken in the institution of HRT in a woman with a history of low grade ESS. Hormonal treatment with aromatase inhibitors may be considered in cases where ER and PR are expressed by the primary tumour and metastases, with possible benefits even in metastatic disease.

• Authors: J M Bréchot, M Kamboucher, M Brauner, M D Destable, F Duperron, J F Morère
• Journal: Revue des maladies respiratoires (Rev Mal Respir) Vol. 24 Issue 1 Pg. 69-72 (Jan 2007) ISSN: 0761-8425 [Print] France
• Vernacular Title: Les métastases pulmonaires de sarcomes utérins peuvent bénéficier d'une hormonothérapie!
• PMID: 17268368 (Publication Type: Case Reports, Journal Article)

Chemical References

• Aromatase Inhibitors
• Nitriles
• Triazoles
• Letrozole

Topics

• Aromatase Inhibitors (therapeutic use)
• Endometrial Neoplasms (pathology)
• Female
• Humans
• Letrozole
• Lung Neoplasms (drug therapy, secondary)
• Middle Aged
• Nitriles (therapeutic use)
• Sarcoma, Endometrial Stromal (drug therapy, secondary)
• Triazoles (therapeutic use)
• Uterine Neoplasms (pathology)